Almost Complete Response with a Single Administration Ac-225-DOTATATE in a Patient with a Metastatic Neuroendocrine Tumor of Unknown Primary

Creative Commons License

ALAN SELÇUK N., Demirci E., Ocak M., Toklu T., Ergen S., KABASAKAL L.

MOLECULAR IMAGING AND RADIONUCLIDE THERAPY, vol.31, no.2, pp.139-141, 2022 (ESCI) identifier identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 31 Issue: 2
  • Publication Date: 2022
  • Doi Number: 10.4274/mirt.galenos.2022.64497
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.139-141
  • Keywords: Ac-225 targeted alpha therapy, neuroendocrine tumors, peptide receptor radionuclide therapy
  • Istanbul University Affiliated: Yes


Neuroendocrine tumors (NETS) are being seen increasingly frequently, and the only known curative treatment method is surgical resection. Peptide receptor radionuclide therapy (PRRT) is a treatment option that the most contributes to progression-free survival and overall survival in metastatic cases.beta-emitting radionuclides are traditionally used for PRRT. Nowadays, alpha particle-emitting radionuclides are being developed, with advantages in terms of very high energy and a short path length, which should theoretically show higher efficacy. In this case; in a patient with NET diagnosis who had multiple (>50) lesions in the abdomen, almost all the lesions disappeared with a single dose application. This paper aims to present a case in which we observed the efficacy of Ac-225-DOTATATE treatment, which is an alpha treatment.